BCT301 in Treating Refractory/Recurrent IgG4-related Disease

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This is an investigator initiated trial to assess the safety and efficacy of BCT301 cell Injection (CAR-iT cells derived from chemically induced pluripotent stem cells) in patients with refractory/recurrent IgG4-related disease.
Epistemonikos ID: 55a1bf5722a5a8c4979cbe89da1adaf9a5fba538
First added on: Sep 01, 2026